The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.
Decentralized trials and remote monitoring, long discussed, but never really taking off until COVID-19 disrupted studies last year, will be under the spotlight at the DIA 2021 Annual Meeting at the end of this month.
While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
The Tufts Center for the Study of Drug Development is out with a new study claiming that the average cost of bringing a new drug to market is around $2.6bn, though some are saying that number seems inflated.
The genomics industry is already separating into two tiers; the
winners are those focused on targets and drug development and which
have products in or near the clinic, as well as strong
partnerships, says analyst